Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Serologic+Tests%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
/vufind/Search/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Serologic+Tests%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
Search /vufind/Search2/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Serologic+Tests%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
PubPharm (10)
1
Serological investigations of blood donors from the city and area around Magdeburg for antibodies against SARS-CoV-2 (COVID-19) : Serological investigations of blood donors from the city and area around Magdeburg for antibodies against SARS-CoV-2 (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Serological investigations of blood donors from the city and area around Magdeburg for antibodies against SARS-CoV-2 (COVID-19) : Serological investigations of blood donors from the city and area around Magdeburg for antibodies against SARS-CoV-2 (COVID-19)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease : A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease : A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines : A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
6
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines : A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccines
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
7
Evaluation of safety and immunogenicity of a Human Papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females. : A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscularly according to a three-dose schedule (Day 0, Week 6, Month 6) in human immunodeficiency virus-infected (HIV+) female subjects aged 15 - 25 years, as compared to Merck’s HPV-6/11/16/18 vaccine (Gardasil®). - HPV-019 PRI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
8
Evaluation of safety and immunogenicity of a Human Papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females. : A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscularly according to a three-dose schedule (Day 0, Week 6, Month 6) in human immunodeficiency virus-infected (HIV+) female subjects aged 15 - 25 years, as compared to Merck’s HPV-6/11/16/18 vaccine (Gardasil®). - HPV-019 PRI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
9
Antibody persistence for GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) administered in healthy adults and adolescents, 6.5 years after first vaccination in the primary study. : A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2-dose schedule in healthy female adolescents or intramuscularly according to a 3-dose schedule in healthy female adults, 6.5 years after first vaccine dose in study HPV-048 PRI (110659). - HPV-081 EXT:048 Y6.5
enthalten in:
WHO International Clinical Trials Registry Platform
| 2014
Wird geladen...
10
Antibody persistence for GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) administered in healthy adults and adolescents, 6.5 years after first vaccination in the primary study. : A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2-dose schedule in healthy female adolescents or intramuscularly according to a 3-dose schedule in healthy female adults, 6.5 years after first vaccine dose in study HPV-048 PRI (110659). - HPV-081 EXT:048 Y6.5
enthalten in:
WHO International Clinical Trials Registry Platform
| 2014
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
10
Aufsätze
10
E-Artikel
10
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
10
610
8
Recruitment Status: Not yet recruiting
8
Study Type: Interventional
6
Phase: Phase 4
2
Medical Condition: Coronavirus disease 2019 (CO...
2
Medical Condition: For active immunization of w...
2
Medical Condition: Healthy volunteers [For acti...
2
Medical Condition: Serological testing of antib...
2
Medical Condition: This study will investigate ...
2
Phase: Phase 2
2
Recruitment Status: Recruiting
2
Study Type: Observational
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2020-
6
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
10
Englisch
Haven't found what you're looking for?
Wird geladen...